[Details Enclosed]
Editor’s Note: At The Daily FWD we’re always looking out for special opportunities we believe you, as a valued subscriber, will want to see. Below you’ll find one from our partners at Behind the Markets. Please note that their opinions may differ from ours. Our #1 Biotech for 2024
(Trading at just $7) Former Wall Street CEO Dylan Jovine may be the best biotech investor on earth... He's responsible for gains like: - 463% on Immunogen
- 205% on Altimmune
- 435% on Chemocentryx
And today, I've got some great news for you. Because Dylan just released his #1 Biotech for 2024. And he says you need to check out this Micro-Cap biotech trading at just $7. Because they hold the patent on a revolutionary new treatment - That's been racking up FDA approvals all of last year. And is predicted to get even more in 2024. The right FDA approval could send this stock SOARING. Click here to get the name and ticker of the stock>>> All the best, Simmy Adelman, Publisher
Behind the Markets | |
| | | | © 2024 Paradigm Press, LLC. 1001 Cathedral Street, Baltimore, MD 21201. By submitting your email address, you consent to Paradigm Press, LLC. delivering daily email issues and advertisements. To end your The Daily FWD e-mail subscription and associated external offers sent from The Daily FWD, feel free to click here. Please note: the mailbox associated with this email address is not monitored, so do not reply to this message. We welcome comments or suggestions at feedback@paradigmpressgroup.com. This address is for feedback only. For questions about your account or to speak with customer service, contact us here or call (844)-731-0984. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized financial advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of a printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. The Daily FWD is committed to protecting and respecting your privacy. We do not rent or share your email address. Please read our Privacy Statement. If you are having trouble receiving your The Daily FWD subscription, you can ensure its arrival in your mailbox by whitelisting The Daily FWD. | | |
No comments:
Post a Comment
Keep a civil tongue.